Bandingkan Harga & Kinerja Grand House Mulia Tbk. (HOMI) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Grand House Mulia Tbk. dan Organon Pharma Indonesia Tbk.: Grand House Mulia Tbk. diperdagangkan di Rp232 (kapitalisasi pasar 384,3 M, volume 24 jam 3,49 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Grand House Mulia Tbk. jauh lebih besar — sekitar 3,7× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| HOMI | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 384,3 M | 104,4 M |
Volume | 3,49 jt | — |
Lot | 34,89 rb | — |
Perputaran | 796,11 jt | — |
Harga Rata-rata | 228,18 | — |
Nilai Transaksi | 796,11 jt | — |
Harga Ekuilibrium Indikatif | 232 | — |
Volume Ekuilibrium Indikatif | 110 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Grand House Mulia Tbk.
PT Grand House Mulia, Tbk (“the Company”) was established in Republic of Indonesia based on the Notarial Deed No. 1 dated January 9, 2006 of Suryati Moerwibowo, S.H., The Company has commercially operated in April 2019.
Selengkapnya di halaman HOMI →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
